Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review
Jessica E Burchette1, Kelly Covert1, Patrick Tu2
1Department of Pharmacy Practice, ETSU Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA.
Objective:
To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis.
Data Sources:
A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations.
Study Selection And Data Extraction:
Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations.
Data Synthesis:
Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non-US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available.Relevance to patient care and clinical practice in comparison with existing drugs:As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis.
Conclusion:
Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.
Insights
Pivmecillinam is effective for treating uncomplicated acute cystitis, offering a valuable option as antimicrobial resistance grows. Higher doses and longer durations show better results for this common urinary tract infection.
Area of Science:
- Pharmacology and Infectious Diseases
- Antimicrobial Resistance Studies
Background:
- Rising resistance to first-line antimicrobials necessitates novel treatment strategies.
- Pivmecillinam offers a new therapeutic option for uncomplicated acute cystitis in the US.
Purpose of the Study:
- To review evidence on pivmecillinam for uncomplicated acute cystitis.
- To discuss its efficacy, safety, and place in therapy.
Main Methods:
- Literature search of PubMed and ClinicalTrials.gov (2000-2024).
- Included English-language RCTs on pivmecillinam for UTIs in adults.
- MeSH terms: mecillinam, pivmecillinam, urinary tract infections.
Main Results:
- Six RCTs support pivmecillinam for acute uncomplicated cystitis (200-400 mg TID for 3-7 days).
- 400 mg doses and longer durations yielded better clinical and bacteriologic cure rates.
- Limited data exist for pyelonephritis; caution advised.
Conclusions:
- Pivmecillinam is a promising agent for uncomplicated acute cystitis.
- Its use may be cost-driven but is encouraged for susceptible uropathogens due to low resistance.
- Considered a key agent when other treatments fail due to resistance.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Hand hygiene
Hand washing...
